β-cell function – Medxy AI

Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study

By MedXY 09/21/2026

This study investigates three-year continuous glucose monitoring trajectories across clinical subgroups of adults with type 1 diabetes to identify factors influencing glycemic control and variability, highlighting the need for individualized management based on CGM data.

Diabetes & Endocrinology news

GLP1R R131Q Variant: A Genetic Key to Preserving β-Cell Function and Enhancing GLP-1RA Efficacy in Type 2 Diabetes

By MedXY 08/26/2026

The gain-of-function GLP1R R131Q variant slows β-cell decline and improves glycemic response to GLP-1 receptor agonists, highlighting its potential role in precision diabetes therapeutics.

Diabetes & Endocrinology news

Durability of β-Cell Function After Cessation of Baricitinib Immunotherapy in New-Onset Type 1 Diabetes

By MedXY 08/22/2026

Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.

Diabetes & Endocrinology news

Early Detection of β-Cell Preservation in New-Onset Type 1 Diabetes: Insights from Serial Dried Blood Spot C-Peptide Sampling in the USTEKID Trial

By MedXY 07/10/2026

Serial dried blood spot C-peptide sampling detects early β-cell preservation in new-onset type 1 diabetes more sensitively than urine C-peptide-to-creatinine ratio or mixed-meal tolerance test.

Diabetes & Endocrinology news

Precision Medicine Enhances Management but Not Complications in Young-Onset Diabetes: Insights from the PRISM Randomized Trial

By MedXY 07/08/2026

The PRISM trial evaluated a precision medicine program using biogenetic markers and multidisciplinary care in Chinese young-onset diabetes patients, improving metabolic control and patient well-being but not reducing complications over three years.

Diabetes & Endocrinology news

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

By MedXY 06/27/2026

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in those with preserved β-cell function.

Clinical Updates Diabetes & Endocrinology news Specialties

Time-Restricted Eating in Type 2 Diabetes: Can a Shorter Eating Window Boost β-Cell Function and Metabolic Health?

By MedXY 08/08/2025

Recent trials suggest that time-restricted eating (TRE) may modestly improve β-cell function and metabolic control in type 2 diabetes, but effects on insulin sensitivity and long-term outcomes remain uncertain.